Tumor News and Research

RSS

Blavatnik Biomedical Accelerator funds advanced biomedical research projects

A few years ago, Andrew Myers' laboratory discovered a new way to synthesize an important class of antibiotics that could one day tackle the toughest, most resistant infections.

20 Aug 2015

MCRI announces winners of cancer crowdsourcing initiative

The Myeloma Crowd Research Initiative (MCRI), an unprecedented collaboration of cancer researchers and patient advocates, today announced the two winners of its first-ever crowdsourcing and patient-led initiative to fund research in high-risk multiple myeloma, a rare malignancy of plasma cells.

19 Aug 2015

EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

EnGeneIC Ltd., an emerging biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of cancer therapeutics, today announced that the first patient has been dosed in its Phase 1 Tailored-EDV trial. The trial is being conducted at the Northern Cancer Institute in Sydney, Australia.

19 Aug 2015

Complete removal of visible tumor improves outcomes in children with high-grade glioma

For children with aggressive brain cancers called high-grade gliomas (HGG), the chances of survival are improved when surgery is successful in eliminating all visible cancer, reports a study in the September issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

19 Aug 2015

LINE-1 jumping gene unusually active in gastrointestinal cancer

Results of a trio of studies done on human cancer tissue biopsies have added to growing evidence that a so-called jumping gene called LINE-1 is active during the development of many gastrointestinal cancers.

19 Aug 2015

Researchers refine breast cancer risk model to give more accurate assessment

A national risk model that gauges a woman's chance of developing breast cancer has been refined to give a more accurate assessment. The revised figures, based on data from more than one million patients, reveal a 300 percent increase in a subset of women whose five-year risk is estimated at 3 percent or higher.

19 Aug 2015

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

OncoSec Medical Incorporated, a company developing DNA-based intratumoral cancer immunotherapies, today announced enrollment of the first patient into the Phase II Investigator Sponsored Trial led by the University of California, San Francisco to assess the anti-tumor activity, safety, and tolerability of the combination of OncoSec's investigational therapy, ImmunoPulse IL-12, and Merck's approved anti-PD-1 agent, KEYTRUDA (pembrolizumab), in patients with unresectable metastatic melanoma.

18 Aug 2015

NCI-MATCH phase II precision medicine trial opens through ECOG-ACRIN

The National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) phase II precision medicine trial, known to doctors as trial EAY131, is open through the ECOG-ACRIN Cancer Research Group.

18 Aug 2015

Dr. Samadi's Prostate Cancer Center now offers Oncotype DX genetic test

Revolutionary genetic test, Oncotype DX from Genomic Health, is now offered at Dr. Samadi's Prostate Cancer Center in New York City.

18 Aug 2015

MGH study reveals effects of combined radiation and chemotherapy on the brain tissue of glioblastoma patients

A study from Massachusetts General Hospital Cancer Center researchers - the first to examine the effects of combined radiation and chemotherapy on the healthy brain tissue of glioblastoma patients - reveals not only specific structural changes within patients' brains but also that the effect of cancer therapy on the normal brain appears to be progressive and continues even after radiation therapy has ceased.

18 Aug 2015

Regulation of tumor microenvironment may offer alternate method for cancer treatment

Scientists know that activation of growth factor receptors like epidermal growth factor receptors (EGFR) promote tumor progression in many types of cancer.

18 Aug 2015

Studies show jumping genes more active during development of gastrointestinal cancers

18 Aug 2015

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

DelMar Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced an increase in funding of up to CDN$287,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) to support an ongoing research project.

17 Aug 2015

Genomic Health announces Medicare coverage for Oncotype DX prostate cancer test

Genomic Health, Inc. today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued its final local coverage determination (LCD) approving coverage of the Oncotype DX prostate cancer test for qualified Medicare patients throughout the United States.

17 Aug 2015

New ISCO-SCCA collaboration to elevate standard of monthly virtual personalized tumor board

The Idaho Society of Clinical Oncology held its annual Board of Directors retreat in Sun Valley, ID on July 24-26, 2015. The focus for the retreat was how to discuss strategies to improve the care of cancer patients in Idaho. During the meeting, ISCO board announced a partnership with the Seattle Cancer Care Alliance to collaborate with ISCO's monthly virtual personalized tumor board.

17 Aug 2015

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

Chiasma, Inc., a U.S. late-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration has accepted for filing the Company's New Drug Application (NDA) for the marketing and sale of octreotide capsules, an oral drug proposed for the maintenance therapy of adult patients with acromegaly.

17 Aug 2015

3D protein structure reveals new drug targets for cancer, neurodegenerative diseases

Protein Kinase C (PKC) is a family of enzymes that controls the activity of other proteins in a cell by attaching chemical tags. That simple act helps determine cell survival or death.

14 Aug 2015

Researchers use advanced photodynamic therapy to combat ovarian cancer in laboratory animals

Researchers at Oregon State University have made a significant advance in the use of photodynamic therapy to combat ovarian cancer in laboratory animals, using a combination of techniques that achieved complete cancer cell elimination with no regrowth of tumors.

14 Aug 2015

Researchers develop new way to personalize treatments for aggressive bladder cancer

Researchers at UC Davis, in collaboration with colleagues at Jackson Laboratory, have developed a new way to personalize treatments for aggressive bladder cancer.

14 Aug 2015

Merck, MD Anderson form strategic clinical research collaboration to evaluate anti-PD-1 therapy

Merck and The University of Texas MD Anderson Cancer Center announced a strategic clinical research collaboration to evaluate Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in combination with other treatments, such as chemotherapy, radiation therapy and/or novel anti-tumor medicines.

14 Aug 2015

Tumor News and Research

Blavatnik Biomedical Accelerator funds advanced biomedical research projects

MCRI announces winners of cancer crowdsourcing initiative

EnGeneIC begins Phase 1 Tailored-EDV trial for advanced solid tumor

Complete removal of visible tumor improves outcomes in children with high-grade glioma

LINE-1 jumping gene unusually active in gastrointestinal cancer

Researchers refine breast cancer risk model to give more accurate assessment

First patient enrolled in Phase II trial of ImmunoPulse IL-12 and pembrolizumab combination therapy

NCI-MATCH phase II precision medicine trial opens through ECOG-ACRIN

Dr. Samadi's Prostate Cancer Center now offers Oncotype DX genetic test

MGH study reveals effects of combined radiation and chemotherapy on the brain tissue of glioblastoma patients

Regulation of tumor microenvironment may offer alternate method for cancer treatment

Studies show jumping genes more active during development of gastrointestinal cancers

DelMar obtains additional funding to support ongoing research project with lead product candidate VAL-083

Genomic Health announces Medicare coverage for Oncotype DX prostate cancer test

New ISCO-SCCA collaboration to elevate standard of monthly virtual personalized tumor board

FDA accepts Chiasma's NDA filing for octreotide capsules for treatment of adult patients with acromegaly

3D protein structure reveals new drug targets for cancer, neurodegenerative diseases

Researchers use advanced photodynamic therapy to combat ovarian cancer in laboratory animals

Researchers develop new way to personalize treatments for aggressive bladder cancer

Merck, MD Anderson form strategic clinical research collaboration to evaluate anti-PD-1 therapy

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News